ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MESO Mesoblast Limited

7.29
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Mesoblast Limited NASDAQ:MESO NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 7.29 7.10 7.34 0 01:00:00

Mesoblast to Host First Quarter Financial Results Webcast and Conference Call

13/11/2017 9:30pm

GlobeNewswire Inc.


Mesoblast (NASDAQ:MESO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Mesoblast Charts.

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced it will report financial results for the first quarter ended September 30, 2017 and provide a corporate update beginning at 4:30 pm ET on Tuesday, November 14, 2017 and 8:30 am AEDT on Wednesday, November 15, 2017.  

The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/59ff897e6afa4a0577a982bb

The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.

To access the call, dial 1 855 881 1339 (US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).

The conference identification code is: 303705.

The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com

About MesoblastMesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.

For further information, please contact:

Julie Meldrum                                                               Corporate Communications                                         Mesoblast Limited                                                        T: +61 3 9639 6036                                                      E: julie.meldrum@mesoblast.com

Schond GreenwayInvestor RelationsMesoblast LimitedT: +1 212 880-2060E: Schond.Greenway@mesoblast.com

1 Year Mesoblast Chart

1 Year Mesoblast Chart

1 Month Mesoblast Chart

1 Month Mesoblast Chart

Your Recent History

Delayed Upgrade Clock